What Fueled The Previous Growth In The Anaphylaxis Treatment Market?
The anaphylaxis treatment market has seen considerable growth due to a variety of factors.
•There has been a robust growth in the anaphylaxis treatment market in the past few years. The market, currently valued at $6.19 billion in 2024, is projected to escalate to $6.61 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 6.9%.
The reasons for this significant growth during the historical period include the rising occurrences of allergic responses, improved identification of anaphylaxis, the increased availability of epinephrine auto-injectors, as well as enhanced public cognizance, education, and professional training in healthcare.
What Is The Expected Growth In The Anaphylaxis Treatment Market Size?
The anaphylaxis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Over the coming years, a substantial increase is anticipated in the size of the anaphylaxis treatment market, with expectations to reach $8.72 billion by 2029, at a compound annual growth rate (CAGR) of 7.2%.
This elevation during the projected period can be accredited to advancements in biologic therapy, personalized treatment strategies, worldwide measures for food safety, patient participation and advocacy, and boosted emergency healthcare services. As for the key themes emerging in the forecast period, they encompass progression in auto-injector technology, the application of telemedicine for managing anaphylaxis, enhanced allergen immunotherapy, the use of biometric wearables to detect allergens, as well as partnerships in allergy research.
What Are the Critical Driver Fuelling the Anaphylaxis Treatment Market's Growth?
The increasing prevalence of food allergies is forecasted to drive the expansion of the anaphylaxis treatment market. Food allergies are an immune response to proteins found in food. Treatments for anaphylaxis aim to prevent severe allergic reactions involving the skin, mucosal surface, respiratory compromise, hypotension, and dysfunction of end-organs. For example, the Centers for Disease Control and Prevention, a US government agency, revealed in January 2023 that in 2021, 31.8% of adults aged 18 and over reported suffering from eczema, a seasonal allergy, or a food allergy. Of these adults, a quarter (25.7%) had a seasonal allergy, 6.2% had a food allergy, and 7.3% had eczema. Furthermore, in August 2024, the Food Standards Agency, a non-ministerial department in the UK, stated that 296 valid case reports were lodged with the Registry from October 2021 to August 27, 2023. This figure likely represents less than 5% of accidental reactions in the UK, and of these reports, 213 (72%) were linked to food triggers. 208 (97.7%) of these reactions occurred in individuals aged 18 or younger while only 28 clinics and 11 A&E departments signed up for platform access. Hence, the escalating prevalence of food allergies is stimulating the expansion of the anaphylaxis treatment market.
How Is the Anaphylaxis Treatment Market segmented?
The anaphylaxis treatment market covered in this report is segmented –
1) By Treatment: Epinephrine, Antihistamines, Steroids, Beta-antagonists, Other Treatments
2) By Product: Tablets, Capsules, Other Products
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By Application: Food Allergy, Pollen Allergy, Dust Mites Allergy, Other Applications
Subsegments:
1) By Epinephrine: Auto-Injectors, Vials Or Syringes
2) By Antihistamines: Oral Antihistamines, Injectable Antihistamines
3) By Steroids: Oral Steroids, Injectable Steroids
4) By Beta-antagonists: Oral Beta-blockers, Injectable Beta-blockers
5) By Other Treatments: Corticosteroids, Intravenous Fluids, Other Supportive Treatments
Pre-Book The Anaphylaxis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Anaphylaxis Treatment Market?
The anaphylaxis treatment market is seeing an emerging trend in the form of advanced product development. Key players in this market are innovating their products to maintain their market standing. As an example, Aquestive Therapeutics Inc., a pharmaceutical company based in the US, earned a Fast Track designation in April 2022 for their AQST-109 drug, which is used to treat severe allergic reactions such as anaphylaxis. The Food and Drug Administration granted this title. Aquestive is proceeding with clinical trials for AQST-109, the only candidate for an epinephrine product taken orally that has shown clinical results on par with autoinjectors (like EpiPen and Auvi-Q) in treating allergic emergencies, anaphylaxis included.
Who Are the Key Players in the Anaphylaxis Treatment Market?
Major companies operating in the anaphylaxis treatment market include:
• Merck & Co. Inc.
• Novartis International AG
• GlaxoSmithKline plc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Bausch Health Companies
• Sun Pharmaceutical Industries Ltd.
• Perrigo Co
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals plc
• Amneal Pharmaceuticals Inc.
• ALK-Abelló A/S
• Amphastar Pharmaceuticals Inc.
• Par Pharmaceutical Inc.
• Genentech Inc.
• Meridian Medical Technologies LLC
• Aquestive Therapeutics Inc.
• Sandoz Inc.
• Adamis Pharmaceutical Corporation
• Impax Laboratories LLC
What Is The Most Dominant Region In The Anaphylaxis Treatment Market?
North America was the largest region in the anaphylaxis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaphylaxis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
